Total debt has been reduced from $5.8B to $3.9B since Q1 2024, lowering D/E to 0.59, though goodwill of $4.8B (35% of assets) and negative retained earnings of -$2.1B indicate lingering acquisition-related strain.
| Total Current Assets | 3.8B | 3.46B | 3.21B | 3.41B | 3.28B | 3.27B | 3.42B | 2.37B | 2.5B | 2.12B | 1.95B |
| Cash & Short-Term Investments | 530M | 545M | 468M | 352M | 345M | 638M | 495M | 334M | 474.8M | 323.4M | 258.8M |
| Cash Only | 530M | 545M | 468M | 352M | 345M | 638M | 495M | 334M | 474.8M | 323.4M | 258.8M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.15B | 940M | 886M | 1.01B | 1B | 1.03B | 1.08B | 889.9M | 709.4M | 601.9M | 630.7M |
| Days Sales Outstanding | 76.73 | 72.77 | 72.85 | 83.46 | 82.91 | 78.76 | 120.09 | 105.77 | 84.43 | 76.04 | 79.01 |
| Inventory | 1.77B | 1.74B | 1.57B | 1.74B | 1.54B | 1.37B | 1.58B | 1.05B | 1B | 1.06B | 875.6M |
| Days Inventory Outstanding | 265.74 | 237.9 | 227.08 | 255.46 | 229.98 | 186.17 | 284.22 | 229.55 | 206.92 | 226.07 | 202.31 |
| Other Current Assets | 0 | 236M | 287M | 310M | 394M | 0 | 11M | 11.1M | 202.7M | 0 | 0 |
| Total Non-Current Assets | 9.76B | 9.9B | 9.4B | 10.96B | 12.21B | 13.2B | 14.28B | 6.61B | 6.45B | 6.82B | 6.15B |
| Property, Plant & Equipment | 1.41B | 1.41B | 993M | 1.03B | 999M | 1.05B | 1.32B | 955.3M | 922.4M | 920.3M | 741.8M |
| Fixed Asset Turnover | 3.58x | 3.35x | 4.47x | 4.31x | 4.42x | 4.52x | 2.49x | 3.21x | 3.32x | 3.14x | 3.93x |
| Goodwill | 4.84B | 4.78B | 4.41B | 5.09B | 5.99B | 6.17B | 6.22B | 2.99B | 2.96B | 2.97B | 2.58B |
| Intangible Assets | 3.2B | 3.41B | 3.68B | 4.49B | 4.84B | 5.59B | 6.39B | 2.48B | 2.45B | 2.67B | 2.62B |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.3M | 12.3M | 9M |
| Other Non-Current Assets | 304M | 304M | 311M | 341M | 378M | 390M | 348M | 185M | 103.1M | 242M | 204M |
| Total Assets | 13.56B | 13.36B | 12.61B | 14.36B | 15.49B | 16.48B | 17.69B | 8.99B | 8.96B | 8.94B | 8.1B |
| Asset Turnover | 0.37x | 0.35x | 0.35x | 0.31x | 0.28x | 0.29x | 0.19x | 0.34x | 0.34x | 0.32x | 0.36x |
| Asset Growth % | 8.77% | 5.9% | -12.17% | -7.29% | -5.99% | -6.87% | 96.9% | 0.32% | 0.18% | 10.38% | - |
| Total Current Liabilities | 1.85B | 1.6B | 1.31B | 1.24B | 1.7B | 1.65B | 2.08B | 818.5M | 970.7M | 632.6M | 618.9M |
| Accounts Payable | 427M | 368M | 296M | 270M | 390M | 416M | 501M | 222.6M | 205.2M | 203.8M | 228.2M |
| Days Payables Outstanding | 58.24 | 50.4 | 42.7 | 39.75 | 58.32 | 56.49 | 90.24 | 48.63 | 42.29 | 43.37 | 52.73 |
| Short-Term Debt | 73M | 74M | 44M | 38M | 388M | 294M | 555M | 24.5M | 29M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 367.6M | 0 | 0 |
| Other Current Liabilities | 0 | 1.16B | 975M | 933M | 924M | 937M | 1.02B | 555M | 736.5M | 169.2M | 307.5M |
| Current Ratio | 2.05x | 2.17x | 2.44x | 2.75x | 1.93x | 1.99x | 1.65x | 2.90x | 2.58x | 3.36x | 3.15x |
| Quick Ratio | 1.10x | 1.08x | 1.25x | 1.35x | 1.02x | 1.16x | 0.89x | 1.62x | 1.55x | 1.68x | 1.73x |
| Cash Conversion Cycle | 284.22 | 260.27 | 257.23 | 299.16 | 254.57 | 208.44 | 314.08 | 286.68 | 249.06 | 258.75 | 228.6 |
| Total Non-Current Liabilities | 5.12B | 5.21B | 5.2B | 6.9B | 6.5B | 7.32B | 7.14B | 2.62B | 2.79B | 516.9M | 452.9M |
| Long-Term Debt | 3.85B | 3.94B | 4.28B | 5.74B | 5.45B | 6.03B | 5.57B | 2.33B | 2.44B | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.64B | 382M | 449M | 567M | 662M | 765M | 900M | 100.8M | 114.6M | 251.9M | 227.5M |
| Other Non-Current Liabilities | 551M | 889M | 477M | 595M | 390M | 533M | 668M | 189.1M | 230.6M | 265M | 225.4M |
| Total Liabilities | 6.97B | 6.81B | 6.52B | 8.14B | 8.2B | 8.97B | 9.22B | 3.44B | 3.76B | 1.15B | 1.07B |
| Total Debt | 3.92B | 4.02B | 4.32B | 5.77B | 5.84B | 6.32B | 6.13B | 2.35B | 2.47B | 0 | 0 |
| Net Debt | 3.39B | 3.47B | 3.85B | 5.42B | 5.49B | 5.68B | 5.63B | 2.02B | 2B | -323.4M | -258.8M |
| Debt / Equity | 0.59x | 0.61x | 0.71x | 0.93x | 0.80x | 0.84x | 0.72x | 0.42x | 0.48x | - | - |
| Debt / EBITDA | 3.39x | 4.31x | 4.73x | 5.66x | 5.47x | 6.20x | 13.92x | 3.44x | 4.05x | - | - |
| Net Debt / EBITDA | 2.93x | 3.73x | 4.22x | 5.32x | 5.15x | 5.57x | 12.80x | 2.95x | 3.28x | -0.70x | -0.48x |
| Interest Coverage | 0.31x | -0.02x | 2.44x | -3.31x | 0.72x | -1.16x | -3.31x | 1.99x | 4.85x | - | - |
| Total Equity | 6.59B | 6.55B | 6.1B | 6.22B | 7.29B | 7.51B | 8.48B | 5.55B | 5.2B | 7.79B | 7.03B |
| Equity Growth % | 10.42% | 7.4% | -2.04% | -14.62% | -2.92% | -11.42% | 52.81% | 6.72% | -33.29% | 10.86% | - |
| Book Value per Share | 13.02 | 13.19 | 12.26 | 12.64 | 14.93 | 15.41 | 19.20 | 14.98 | 16.57 | 21.87 | 19.73 |
| Total Shareholders' Equity | 6.59B | 6.55B | 6.1B | 6.22B | 7.29B | 7.51B | 8.48B | 5.55B | 5.2B | 7.79B | 7.03B |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.05B | 7.48B |
| Retained Earnings | -2.07B | -2.18B | -1.95B | -2.29B | -1.06B | -979M | -477M | 84.3M | 16.4M | 0 | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -219M | -141M | -771M | -266M | -392M | -209M | 303M | -173.7M | -222.2M | -256.6M | -456.9M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Elevated debt and competition
Total debt fell from $5.8B in Q1 2024 to $3.9B in Q2 2026, reducing D/E from 0.95 to 0.59, as per recent financial statements, indicating a steady deleveraging path.
The sequential decline in total debt, coupled with a stable equity base, suggests that management is prioritizing debt reduction, likely using operating cash flow. This trend is consistent with the improving cash flow signal from the income statement analysis, where FCF turned positive. However, the pace of deleveraging appears moderate, and the absolute debt level remains substantial relative to equity, warranting continued monitoring.
Debt-to-equity improved to 0.59 in Q2 2026 from 0.96 in Q2 2024, yet total debt of $3.9B still exceeds equity, as reported in SEC filings, indicating persistent leverage.
The reduction in leverage is a positive sign, but the debt load remains a constraint, especially given the negative retained earnings and the need to fund innovation. The interest burden likely continues to pressure net income, as evidenced by the negative ROE. Investors should monitor whether the company can sustain this deleveraging while also investing in growth initiatives.
Goodwill of $4.8B represents 35% of total assets in Q2 2026, per balance sheet data, highlighting the significant role of acquisitions in the company's asset base.
The large goodwill balance, stemming from the Bayer acquisition, exposes the balance sheet to potential impairment risk if growth expectations are not met. However, the recent revenue acceleration and margin expansion may mitigate that risk. The modest PPE of $1.4B suggests an asset-light manufacturing model, but the high fixed-cost base indicated in the company intelligence suggests otherwise, implying that some assets may be leased or off-balance-sheet.
Retained earnings remain deeply negative at -$2.1B in Q2 2026, as per financial statements, yet total equity of $6.6B is supported by paid-in capital, indicating a history of losses.
The negative retained earnings reflect cumulative GAAP losses, largely due to amortization and interest expenses. However, the equity base is stable, and the recent improvement in operating performance may gradually reduce the deficit. The absence of dividends and buybacks, as noted in the cash flow analysis, suggests that all earnings are being retained to support deleveraging and reinvestment.
Current ratio stands at 2.05 in Q2 2026, down from 3.29 in Q1 2024, but cash of $530M provides a cushion, as per recent balance sheet data, against short-term obligations.
The current ratio, while declining, remains above 2, indicating adequate short-term liquidity. However, the cash balance is relatively modest compared to total debt, and the company may need to rely on operating cash flow to meet obligations. The improving cash flow signal suggests that liquidity is not an immediate concern, but the trend in the current ratio warrants monitoring.
Goodwill of $4.8B, roughly 35% of total assets, as per balance sheet data, represents a significant impairment risk if the acquired businesses underperform, potentially distorting equity.
The large goodwill balance from the Bayer acquisition is a non-cash asset that may be subject to impairment if cash flow projections are not met. While recent performance has improved, the competitive pressures in the pet health market and the company's historical growth lag suggest that impairment testing could result in charges. Investors should monitor the company's segment performance and any indicators of impairment in future disclosures.
Quick answers to the most common questions about buying ELAN stock.
As of 2025, Elanco Animal Health Incorporated (ELAN) had total assets of $13.36B including $3.46B in current assets.
Elanco Animal Health Incorporated (ELAN) carries total debt of $4.02B, offset by $545.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Elanco Animal Health Incorporated (ELAN) has total shareholders' equity (book value) of $6.55B ($13.19 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Elanco Animal Health Incorporated (ELAN) reported a current ratio of 2.17x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.